Prognostic value of c-erb-2 immunohistochemistry expression in patients with primary breast cancer and adjuvant treatment with tamoxifen.

Authors

  • Andreia Antunes Serviços de Ginecologia e de Anatomia Patológica, Hospitais da Universidade de Coimbra, Coimbra.
  • Teresa Silva
  • Isabel Godinho
  • Natália Amaral
  • Calos Oliveira

DOI:

https://doi.org/10.20344/amp.1100

Abstract

The c-erb2 proto-oncogene is a member of the epidermal growth factor receptor family and has been associated with a more aggressive breast tumour biology and resistance to some types of treatments.To evaluate the prognostic value of c-erb-2 receptor, from primary breast cancer on tamoxifen therapy.We examined 66 paraffin-embedded sections from primary breast cancers. Patients were treated with surgery plus adjuvant treatment with tamoxifen; 58% had also received chemotherapy and/or radiotherapy. Membrane staining for c-erb-2 was evaluated by immunohistochemistry and overall survival and relapse-free survival were compared between positives and negatives for c-erb-2.43,9% of tumours over expressed c-erb-2 receptor, but this was not associated with a worse prognosis on overall survival either on relapse free-survival, with a p value of 0,15 and 0,2 respectively.There is not any advantage to determine c-erb-2 as a prognostic factor on overall survival either on relapse free-survival. Attending the homogenous characteristics between both groups with any statistical differences according age.

Downloads

Download data is not yet available.

How to Cite

1.
Antunes A, Silva T, Godinho I, Amaral N, Oliveira C. Prognostic value of c-erb-2 immunohistochemistry expression in patients with primary breast cancer and adjuvant treatment with tamoxifen. Acta Med Port [Internet]. 2004 Aug. 31 [cited 2024 Nov. 13];17(4):271-6. Available from: https://actamedicaportuguesa.com/revista/index.php/amp/article/view/1100

Issue

Section

Arquivo Histórico